Abstract 353P
Background
Glioblastoma has a poor survival rate around 40% after one year since diagnosis and 17% in the second year. However, studies about treatment of Temozolomide to improve outcome in patients with glioblastoma remains unclear. The aim of the study is to know the overall survival of Temozolomide treatment of glioblastoma, specifically in elderly patients.
Methods
Two reviewers independently extracted studies from online databases PubMed, PMC and Scopus using combinations of keywords related to Temozolomide, glioblastoma, elderly, and survival. Studies that were extracted will be analyzed and selected according to inclusion criteria such as cohort and randomized clinical trial studies in the last 10 years. We excluded systematic reviews, meta-analysis, case series, case report, and animal study. We included studies that investigate the combination of radiotherapy and Temozolomide. Quality of each included study is assessed using the Newcastle-Ottawa Scale (NOS) and Cochrane review for Randomized controlled trial (RCT).
Results
Five studies were extracted from 32 initial eligible one. All five studies included were in good quality. Four of 5 studies showed that Temozolomide's overall survival rate increased significantly. In one of the cohort studies, Temozolomide with radiotherapy compared to radiotherapy alone, 2-year survival rate were increased from 14% to 41%. However, one of 5 studies reported negative result.
Conclusions
In conclusion temozolomide may increase overall survival rate in elderly patients with glioblastoma. However, further RCT studies are needed confirm this finding.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.